Scientists from the Centre "Bioengineering" of RAS filled nanoparticles on the basis of kin living organism polysaccharide chitosan antibiotic doxorubicin, which is used in cancer chemotherapy. This will reduce the negative effects of the drug while maintaining its anticarcinogenic activity.
It is well known that nano-drug delivery systems can improve the therapy of many diseases. With these drugs able to cross various biological barriers (including cellular and nuclear membranes) delivered targeted to infected cells and generally stay in the body longer. But working with solutions of anticancer drugs in its pure form is not always possible — many drugs have a number of serious shortcomings. For example, doxorubicin (DOX) is rapidly degraded in the bloodstream, plus cardio and nephrotoxicity.
Traditionally, these scientists are trying to solve the problem by linking the drug with some inert carrier for the body. Russian team of scientists from the Centre "Bioengineering" Russian Academy of Sciences under the direction of AV Ilina As such carrier investigated modified chitosan — hyaluronic acid polymer, which typically receive pharmacology processing shell shrimps and crabs.
Nanoparticles filled doxorubicin produced by the following procedure: The chitosan attached to succinic acid remains, then from this modified chitosan nanoparticles obtained suspension. And in the formed nanoparticles were put antibiotic molecules. It was found that 1 mg of nanoparticles can attach up to 170 mg of doxorubicin. To see how the break nanoparticles loaded with an antibiotic inside the cell, they are labeled with fluorescein.
Tests in cell cultures showed that the activity of DOX in the nanoparticles is comparable with the activity of doxorubicin dissolved in water. In addition to the cells equal DOX concentration in soluble form in the nanoparticles and the drug at the same rate was in the cell nucleus. In the analysis of the functional activity of scientists found no difference between the nanoparticles and DOX-loaded DOX, indicating that the full safety of DOX when incorporated into a particle.
Thus, the modified chitosan nanoparticles can efficiently bind and deliver doxorubicin antibiotic, not only in the cell itself, but also in its core. Thus anticarcinogenic activity of antibiotic adsorbed nanoparticles is not reduced. All this allows, first, to increase the circulation time of the antibiotic in the blood, which has a positive effect on the efficiency of delivery to the cells and hence the therapeutic effect. Second, it helps to reduce its toxicity in vivo.
This work was supported by RFBR (grant number 10-04-13301-RT_omi, 09-04-00895a) and the Federal Target Program "Research and scientific-pedagogical personnel of innovative Russia" for 2009-2013, the contract P730.
Source of information:
A. Ilyin, A. Zubarev, D. Kurek, A. Leva, VP Varlamov "Nanoparticles based succinylated chitosan with doxorubicin: the formation and properties." Russian Nanotechnology, 2012. V. 7. № 1-2.